NCT05911464 - A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

248

Participants

Timeline

Start Date

March 2, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

HS-10386

Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai